The Uganda Medicinal Cannabis Consortium exists to help Uganda implement medicinal cannabis properly — as healthcare, not hype.
The Uganda Medicinal Cannabis Consortium is a patient-first, healthcare-oriented platform working with Uganda’s Ministry of Health to support the responsible implementation of the country’s medicinal cannabis framework. UMCC brings together Ugandan leaders, clinicians, researchers, regulators, patient advocates, and responsible licensed operators around a shared objective: to ensure that medicinal cannabis in Uganda develops first as a patient-safety and public-health issue, not simply as a commodity or export opportunity.
Uganda is at an important regulatory moment. Medicinal cannabis is increasingly accepted in regulated international markets, but many countries have moved faster than their health systems, clinicians, regulators, and patient-safety structures were prepared for. UMCC supports a disciplined Ugandan approach that combines lawful production, imports, and export with domestic patient access, clinician education, evidence generation, pharmacovigilance, quality standards, and prevention of harm.
UMCC’s position is simple: Uganda should not build a cannabis sector that is export-only, commercially led, or disconnected from local health needs. Uganda has the opportunity to create a medicinal cannabis framework that is scientifically credible, clinically responsible, economically meaningful, and nationally beneficial.
Patients must be the central reason for any medicinal cannabis framework. Product development, prescribing systems, dispensing pathways, research, education, and commercial activity should all be judged against the question of whether they protect and responsibly serve patients.
Medicinal cannabis policy should be grounded in clinical evidence, international experience, Uganda-specific research, real-world observational data where practical, and transparent medical guidance. Claims should be disciplined, careful, and medically responsible.
Patient safety, product quality, controlled access, prevention of misuse, pharmacovigilance, and adverse-event reporting should be embedded from the outset. A credible framework must show not only how patients may benefit, but how risks are managed.
The framework should serve Uganda’s national interests: public health, responsible economic development, local skills, research capacity, pharmaceutical-sector growth, and the protection of Uganda’s international reputation.
UMCC is built around three linked elements. A small Uganda-led Steering Council creates accountability and local legitimacy. A larger Technical Advisory Network brings deeper expertise without making the formal governance body too large. A lean Secretariat ensures that UMCC produces useful work rather than simply convening conversations.
7–9 members
Uganda-led governance, credibility, priorities, and mission discipline. The Council sets strategic direction, protects the patient-first and safety-first mission, and provides a credible Ugandan face to government, clinicians, patients, regulators, and international partners — balanced across public-health, clinical, legal, patient, research, enforcement, and responsible industry perspectives.
20–35 people over time
Ugandan and international expertise organized around UMCC’s workstreams — from clinical education and pharmacovigilance to registry design, quality standards, and regulatory benchmarking. Each member is linked to at least one practical workstream, subgroup, or deliverable. International experts support Ugandan leadership rather than defining it from outside.
Lean and focused
Coordination, documentation, stakeholder engagement, and follow-through. The Secretariat keeps workstreams focused on deliverables and members’ time respected, so that participation is meaningful and UMCC’s output is practical.
Industry should not hold a majority of Steering Council seats, and the Chair should not be an operator. Patient, clinical, legal, research, and public-health voices are structurally protected. Industry participation is transparent, conflicts of interest are declared, and policy recommendations are framed in the public interest — not around the needs of any single company.
UMCC works constructively with government and regulators. Its role is to provide technical input, international experience, stakeholder coordination, and practical recommendations — not to replace the authority of the Ministry of Health, the National Drug Authority, or any other competent government body.